180 related articles for article (PubMed ID: 25901431)
21. ABVD chemotherapy of Hodgkin's disease.
Molnár Z; Schneider T; Várady E; Fleischmann T
Neoplasma; 1997; 44(4):263-5. PubMed ID: 9473781
[TBL] [Abstract][Full Text] [Related]
22. Membranous nephropathy in Hodgkin's disease in complete remission.
Gómez-Campderá FJ; López-Gómez JM; Jofre R; Flores E
Nephron; 1994; 68(3):392. PubMed ID: 7530813
[No Abstract] [Full Text] [Related]
23. Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin's lymphoma: National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group.
Meyer RM; Gospodarowicz MK; Connors JM; Pearcey RG; Bezjak A; Wells WA; Burns BF; Winter JN; Horning SJ; Dar AR; Djurfeldt MS; Ding K; Shepherd LE; ;
J Clin Oncol; 2005 Jul; 23(21):4634-42. PubMed ID: 15837968
[TBL] [Abstract][Full Text] [Related]
24. Escalated BEACOPP in advanced Hodgkin's lymphoma.
Casasnovas O; Coiffier B
Lancet; 2012 May; 379(9828):1767-8. PubMed ID: 22480757
[No Abstract] [Full Text] [Related]
25. Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an intergroup trial.
Duggan DB; Petroni GR; Johnson JL; Glick JH; Fisher RI; Connors JM; Canellos GP; Peterson BA
J Clin Oncol; 2003 Feb; 21(4):607-14. PubMed ID: 12586796
[TBL] [Abstract][Full Text] [Related]
26. How can outcomes be improved for older patients with Hodgkin lymphoma?
Evens AM; Hong F
J Clin Oncol; 2013 Apr; 31(12):1502-5. PubMed ID: 23509323
[No Abstract] [Full Text] [Related]
27. FDG-PET in bleomycin-induced pneumonitis following ABVD chemotherapy for Hodgkin's disease--a useful tool for monitoring pulmonary toxicity and disease activity.
Buchler T; Bomanji J; Lee SM
Haematologica; 2007 Nov; 92(11):e120-1. PubMed ID: 18024389
[TBL] [Abstract][Full Text] [Related]
28. Pediatric Hodgkin's disease.
Oliapuram Jose B; Koerner P; Bertolone S; Patel CC; Spanos WJ; Paris KJ; Silverman CL; Yashar CM
J Ky Med Assoc; 2004 Mar; 102(3):104-6. PubMed ID: 15067795
[TBL] [Abstract][Full Text] [Related]
29. Post-ABVD/pre-radiotherapy (18)F-FDG-PET provides additional prognostic information for early-stage Hodgkin lymphoma: a retrospective analysis on 165 patients.
Ciammella P; Filippi AR; Simontacchi G; Buglione M; Botto B; Mangoni M; Iotti C; Merli F; Marcheselli L; Bisi G; Ricardi U; Versari A
Br J Radiol; 2016; 89(1061):20150983. PubMed ID: 27022777
[TBL] [Abstract][Full Text] [Related]
30. Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin's lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial.
Behringer K; Goergen H; Hitz F; Zijlstra JM; Greil R; Markova J; Sasse S; Fuchs M; Topp MS; Soekler M; Mathas S; Meissner J; Wilhelm M; Koch P; Lindemann HW; Schalk E; Semrau R; Kriz J; Vieler T; Bentz M; Lange E; Mahlberg R; Hassler A; Vogelhuber M; Hahn D; Mezger J; Krause SW; Skoetz N; Böll B; von Tresckow B; Diehl V; Hallek M; Borchmann P; Stein H; Eich H; Engert A; ; ;
Lancet; 2015 Apr; 385(9976):1418-27. PubMed ID: 25539730
[TBL] [Abstract][Full Text] [Related]
31. Chemotherapy only in early-stage Hodgkin lymphoma: more relapses but "same" (or possibly worse) survival--reconsidering the misguided trend to omit radiotherapy.
Yahalom J
Curr Hematol Malig Rep; 2014 Sep; 9(3):212-6. PubMed ID: 24939521
[TBL] [Abstract][Full Text] [Related]
32. Prognostic Implication of the Absolute Lymphocyte to Absolute Monocyte Count Ratio in Patients With Classical Hodgkin Lymphoma Treated With Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine or Equivalent Regimens.
Vassilakopoulos TP; Dimopoulou MN; Angelopoulou MK; Petevi K; Pangalis GA; Moschogiannis M; Dimou M; Boutsikas G; Kanellopoulos A; Gainaru G; Plata E; Flevari P; Koutsi K; Papageorgiou L; Telonis V; Tsaftaridis P; Sachanas S; Yiakoumis X; Tsirkinidis P; Viniou NA; Siakantaris MP; Variami E; Kyrtsonis MC; Meletis J; Panayiotidis P; Konstantopoulos K
Oncologist; 2016 Mar; 21(3):343-53. PubMed ID: 26921291
[TBL] [Abstract][Full Text] [Related]
33. [Positron emission tomography-guided treatment in early-stage favorable Hodgkin lymphoma: final results of the German Hodgkin Study Group].
Frerker B; Hildebrandt G
Strahlenther Onkol; 2020 May; 196(5):488-491. PubMed ID: 32170351
[No Abstract] [Full Text] [Related]
34. [Feasibility study of application of international prognostic score on prediction of prognosis for advanced Hodgkin's lymphoma].
Fu XH; Wang SS; Huang Y; Wang B; Huang HQ; Zhang L; Sun XF; Xu RH; Lin TY
Ai Zheng; 2006 Aug; 25(8):1013-8. PubMed ID: 16965685
[TBL] [Abstract][Full Text] [Related]
35. Feasibility and efficacy of dose-dense and dose-intense ABVD for high-risk patients with advanced Hodgkin lymphoma.
D'Arco AM; Califano C; Barone L; Belsito Petrizzi V; Iovino V; Langella M; Maglione V; Rivellini F; De Lorenzo S
Br J Haematol; 2015 Nov; 171(4):662-5. PubMed ID: 25873239
[No Abstract] [Full Text] [Related]
36. Treatment of lymphocyte-predominant Hodgkin lymphoma.
Engert A
Ann Oncol; 2008 Jun; 19 Suppl 4():iv45-6. PubMed ID: 18519402
[No Abstract] [Full Text] [Related]
37. [Classic Hodgkin's lymphoma in post-treatment hairy cell leukemia: report of a case].
Chen DB; Shen DH
Zhonghua Bing Li Xue Za Zhi; 2011 Dec; 40(12):848-9. PubMed ID: 22336215
[No Abstract] [Full Text] [Related]
38. Are ABVD and MOPP/ABV truly equivalent for treating Hodgkin's disease at advanced stages?
Andrieu JM; Colonna P
J Clin Oncol; 1998 Jun; 16(6):2283. PubMed ID: 9626234
[No Abstract] [Full Text] [Related]
39. Hodgkin's disease of appendix: report of a case.
Umer MA; Date RS; Mellor S; Nair B; Ward JB
Colorectal Dis; 2009 Nov; 11(9):985-7. PubMed ID: 19175635
[TBL] [Abstract][Full Text] [Related]
40. Early versus late intensification for patients with high-risk Hodgkin lymphoma-3 cycles of intensive chemotherapy plus low-dose lymph node radiation therapy versus 4 cycles of combined doxorubicin, bleomycin, vinblastine, and dacarbazine plus myeloablative chemotherapy with autologous stem cell transplantation: five-year results of a randomized trial on behalf of the GOELAMS Group.
Arakelyan N; Berthou C; Desablens B; de Guibert S; Delwail V; Moles MP; Quittet P; Jais JP; Colonna P; Andrieu JM;
Cancer; 2008 Dec; 113(12):3323-30. PubMed ID: 18988286
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]